摘要
血脑屏障的存在限制循环中药物向大脑的渗透,给中枢神经系统疾病的治疗造成巨大挑战。近年来,研究人员发现脑毛细血管内皮细胞存在一类特异性高表达受体,能将循环中特定物质转运到脑内。转铁蛋白受体1 (Transferrin Receptor 1, TfR1)即是其中之一,基于TfR1单克隆抗体的抗体融合蛋白显示了治疗阿尔茨海默病等疾病的潜力,激发了利用TfR1靶向脑内递送药物的研究。本文旨在论述靶向TFR1抗体进行药物脑内递送的研究进程,从而为TfR1抗体药物运载平台的开发提供相关理论基础。
The existence of blood brain barrier (blood brain barrier, BBB) limited the penetration of circulating drugs into the brain, which poses a great challenge to the treatment of central nervous system diseases. In recent years, researchers have found that brain capillary endothelial cells have a class of specific highly expressed receptors, which can transport specific substances in the circulation to brain. As a member of them, Transferrin Receptor 1 has become a research hotspot. Antibody fusion proteins based on TfR1 monoclonal antibodies have shown potential for the treatment of diseases such as Alzheimer’s disease. Thus it stimulated the research of using TfR1 to deliver drugs to the brain. This paper aims to discuss the research process of drug delivery in brain targeting TfR1 antibody, so as to provide a relevant theoretical basis for the development of TfR1 antibody drug delivery platform.
出处
《药物资讯》
2022年第3期137-145,共9页
Pharmacy Information
